Niclosamide ethanolamine improves diabetes and diabetic kidney disease in mice

作者：Han, Pengxun; Shao, Mumin; Guo, Lan; Wang, Wenjing; Song, Gaofeng; Yu, Xuewen; Zhang, Chunlei; Ge, Na; Yi, Tiegang; Li, Shunmin; Du, Heng^*; Sun, Huili^*

来源：American Journal of Translational Research, 2018, 10(4): 1071-1084.

• Niclosamide ethanolamine salt
• diabetes
• diabetic kidney disease

Diabetes and its renal complications are major medical challenges worldwide. There are no effective drugs currently available for treating diabetes and diabetic kidney disease (DKD), especially in type 1 diabetes (T1D). Evidence has suggested that niclosamide ethanolamine salt (NEN) could improve diabetic symptoms in mice of type 2 diabetes (T2D). However, its role in T1D and DKD has not been studied to date. Here we report that NEN could protect against diabetes in streptozotocin (STZ) induced T1D mice. It increased serum insulin levels, corrected the unbalanced ratio of alpha-cells to beta-cells, and induced islet morphologic changes under diabetic conditions. In addition, NEN could impede the progression of DKD in T1D. Specifically, it reduced urinary albumin levels, NAG, NGAL and TGF-beta 1 excretion, ameliorated renal hypertrophy, alleviated podocyte dysfunction, and suppressed the renal cortical activation of mTOR/4E-BP1 signaling pathway. Moreover, it is hepatoprotective and does not exhibit heart toxicity. Therefore, these findings open up a completely novel therapy for diabetes and DKD.

• 出版日期2018
• 单位广州中医药大学